After a successful meeting with the Food and Drug Administration last month, biopharmaceutical firm Palatin Technologies got the go-ahead to file a biologics license application this summer for its monoclonal antibody infection imaging agent,
After a successful meeting with the Food and Drug Administration last month, biopharmaceutical firm Palatin Technologies got the go-ahead to file a biologics license application this summer for its monoclonal antibody infection imaging agent, LeuTech. The company met with the FDAs Center for Biologic Evaluation and Research in Rockville, MD, and the agency reviewed Palatins phase III trial data for LeuTech for the diagnosis of equivocal appendicitis. Palatin hopes LeuTech will be available for sale by mid-summer 2000.
The FDAs permission to proceed further enhances the Princeton, NJ, companys R&D momentum, as it comes on the heels of the companys May 17 announcement that it had signed a letter of intent for a marketing alliance with St. Louis-based Mallinckrodt (SCAN 5/26/99).
© 1999 Miller Freeman, Inc.All rights reserved.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.